What Is the Natural Course of Idiopathic Pulmonary Fibrosis?. Ann Intern Med. 2005;142:I-23. doi: 10.7326/0003-4819-142-12_Part_1-200506210-00002
Download citation file:
Published: Ann Intern Med. 2005;142(12_Part_1):I-23.
Idiopathic pulmonary fibrosis (IPF) is an uncommon disease in which the lungs become scarred and stiff for no apparent reason. Patients note shortness of breath and cough, and many eventually die of lung failure. Treatment may include medications to decrease inflammation or further scarring or lung transplantation. How IPF naturally worsens over time is uncertain because the disease is uncommon and many patients receive a diagnosis in more advanced stages of disease. The researchers of this study previously performed a study in which patients with mild to moderate IPF were randomly assigned to take an experimental treatment or a placebo. The study focused on whether patients improved with treatment. However, the researchers realized that observing the patients who took placebo could provide valuable information about what happens over time to patients with untreated IPF.
To see how IPF naturally worsens over time in a large number of patients with mild to moderate disease.
168 patients randomly assigned to receive placebo in a study of treatment for IPF. Most were white men.
The researchers collected information on patients' lung function and symptoms every 12 weeks from the time the patients enrolled in the study until the study's conclusion (about 1.5 years). They also collected information on the number of hospitalizations and deaths.
Patients' lung function did not generally worsen over the observation period. About one third of patients were hospitalized, many more than once; many hospitalizations were for presumed infection. About 1 in 5 patients died, almost half within weeks of the first worsening of symptoms.
The researchers could not provide detailed information about the reasons patients were hospitalized and why they died. The study included only patients who had not previously improved with steroids. The findings may not apply to patients who did not previously take steroids or to those who took steroids and improved.
IPF does not always slowly worsen over time. Instead, many patients with IPF remain stable for long periods, then suddenly get worse and die. This pattern suggests that patients with IPF who do not improve with steroids should be monitored closely and might possibly undergo lung transplantation while their symptoms are still relatively mild.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Pulmonary/Critical Care, Interstitial Lung Disease.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only